<code id='48AC8335A6'></code><style id='48AC8335A6'></style>
    • <acronym id='48AC8335A6'></acronym>
      <center id='48AC8335A6'><center id='48AC8335A6'><tfoot id='48AC8335A6'></tfoot></center><abbr id='48AC8335A6'><dir id='48AC8335A6'><tfoot id='48AC8335A6'></tfoot><noframes id='48AC8335A6'>

    • <optgroup id='48AC8335A6'><strike id='48AC8335A6'><sup id='48AC8335A6'></sup></strike><code id='48AC8335A6'></code></optgroup>
        1. <b id='48AC8335A6'><label id='48AC8335A6'><select id='48AC8335A6'><dt id='48AC8335A6'><span id='48AC8335A6'></span></dt></select></label></b><u id='48AC8335A6'></u>
          <i id='48AC8335A6'><strike id='48AC8335A6'><tt id='48AC8335A6'><pre id='48AC8335A6'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:89
          MORE Red Blood Cells
          Adobe

          LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

          In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

          advertisement

          The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Mass General totes up its waste in a move to tackle climate change
          Mass General totes up its waste in a move to tackle climate change

          OnanAugustThursdayin2021,deepintothepandemic,twoMassachusettsGeneralHospitaldoctorsstoodgowned,glove

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Ionis has late

          AdobeIonisPharmaceuticals,aCaliforniabiotechthathasspearheadedthedevelopmentofRNA-targetingmedicines